Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • rjohnp
    Member
    • Jan 2013
    • 16

    #16
    Originally posted by Cramsmith View Post
    So I saw in reference to some performance data on the IonTarget Seq Exome, the poster presented and ASHG, by LT. So they had a metric on the poster Ts:Tv, I did not at first get it, but now I believe it to be just a measure of perfomance, i.e. that you captured appropriate fractions of the exome and the predicted ration of Ts:Tv is present.

    Is that correct in thinking that it is just a q.c. score to see how your seq exp. performed.
    Ts/Tv refers to the ratio between transitions and transversions, the two classes of nucleotide chemical changes. Shown below (shamelessly nicked from http://en.wikipedia.org/wiki/Transition_%28genetics%29)



    Changes where the base remains e.g. a purine A>G transition are more liley to occur through various chemical changes, than a change from purine to pyrimidine (A>T). Thus, Ts/Tv tends to be ca. 4, though this does vary in targetted experiments such as whole-exome.

    Random sequencing errors would (presumably, depending on the cause) cause both classes equally, and so ts/tv would trend towards 1.

    Basically, yes, it's a QC thing.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
      by SEQadmin2



      Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

      Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
      ...
      10-14-2026, 09:55 AM
    • SEQadmin2
      New Genomics Technologies Take Aim at Long-Standing Limits
      by SEQadmin2


      Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

      We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
      ...
      09-28-2026, 10:25 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 10-22-2026, 11:13 AM
    0 responses
    42 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-22-2026, 10:48 AM
    0 responses
    32 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-15-2026, 10:52 AM
    0 responses
    44 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-14-2026, 05:39 AM
    0 responses
    45 views
    0 reactions
    Last Post SEQadmin2  
    Working...